



UNICHEM
LABORATORIES LTD.

November 14, 2019

Department of Corporate Services
Bombay Stock Exchange Ltd
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400 001

National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India {Listing Obligations and Disclosure Requirements} Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosure of Related Party Transactions on a consolidated basis for half year ended September 30, 2019 drawn in accordance with applicable Accounting Standards.

Kindly take the same on your records.

Thanking you,
For **Unichem Laboratories Limited**

Pradeep Bhandari
Head- Legal & Company Secretary



UNICHEM LABORATORIES LIMITED

Notes forming part of standalone financial statements for the half year ended 30th September, 2019

44 RELATED PARTY DISCLOSURES


Disclosure of related parties / related party transactions pursuant to Ind AS 24 "Related Party Disclosure".

a) List of related parties

<p>(i) Subsidiaries of the Company (Wholly Owned) :</p> <p>Niche Generics Limited. (United Kingdom) Unichem SA Pty. LTD. (South Africa) Unichem Farmaceutica Do Brasil Ltda (Brazil) Unichem Pharmaceuticals (USA) Inc. (USA) Unichem Laboratories Ltd (Ireland) Unichem (China) Pty Ltd (w.e.f. 27.06.2019)</p>	<p>(ii) Enterprises under significant influence of key management personnel as defined in (iii) (disclosed to the extent of transactions)</p> <p>Uni - Distributors Pvt. Ltd. Elemage Wellness LLP Adiwasi Unnati Mandal Uni Trust Also Refer note (f)</p>
<p>(iii) Key management personnel and their relatives: (disclosed to the extent of transactions)</p> <p>Dr. Prakash A. Mody (Chairman & Managing Director - CMD, Promoter) Mrs Anita Mody (Spouse of CMD) Ms Supriya Mody (Daughter of CMD) Ms. Suparna Mody (Daughter of CMD) Mr. Dilip J. Kunkolienkar (Director - Technical)</p>	<p>(iv) Independent Directors:</p> <p>Dr. (Mrs.) B. Kinnera Murthy Mr. Anand Y. Mahajan Mr. Prafull Anubhai Mr. Prafull D Sheth</p>
<p>(v) Post-employment benefit plans:</p> <p>Unichem Laboratories Ltd- Employees Gratuity Fund Unichem Laboratories Ltd- Employees Superannuation Fund</p>	<p>(vi) Key management personnel and their relatives as per Companies Act, 2013.</p> <p>Mr. Pradeep Bhandari (Head- Legal & Company Secretary) (w.e.f. 01.08.2019) Mrs. Neema Thakore (Head - Legal & Company Secretary) (upto 31.07.2019) Mr. Sandip R.Ghume (Dy. Chief Financial Officer)</p>

b) Disclosure of related party transactions :

Particulars	Rs in Lakhs
	YTD Sep'2019
<p>i) Sale of finished goods/solvents (Net of returns)</p> <p>Subsidiaries</p> <p>Niche Generics Limited. 479.08 Unichem SA Pty. LTD. 516.10 Unichem Farmaceutica Do Brasil Ltda 745.17 Unichem Pharmaceuticals (USA) Inc. 26,258.79</p> <p style="text-align: right;">27,999.14</p>	
<p>ii) Recovery of Expenses - Re-imburements(excluding indirect tax)</p> <p>Elemage Wellness LLP 2.35</p> <p style="text-align: right;">2.35</p>	
<p>iii) Investments made (including guarantee commission & ESOP)</p> <p>Subsidiary</p> <p>Unichem Farmaceutica Do Brasil Ltda 59.56 Unichem Pharmaceuticals (USA) Inc. 5.37 Unichem Laboratories Ltd (Ireland) 11.67 Niche Generics Limited. 143.73 Unichem (China) Pty Ltd 220.33</p>	
<p>iv) Guarantees to banks - given /(reduced)</p> <p>On behalf of Subsidiary Company</p> <p>Unichem Pharmaceuticals (USA) Inc. (21,369.00) Unichem Laboratories Ltd (Ireland) (240.87)</p> <p style="text-align: right;">(21,609.87)</p>	
<p>v) Rent & Maintenance Paid (excluding indirect taxes)</p> <p>Relative of Key Management Personnel</p> <p>Mrs Anita Mody 9.21</p> <p>Enterprise under significant influence of Key Management Personnel</p> <p>Uni - Distributors Pvt. Ltd. 5.77 Uni Trust 4.50</p> <p style="text-align: right;">19.48</p>	
<p>vi) Managerial remuneration (including defined contribution plan)</p> <p>Key Management Personnel</p> <p>Dr. Prakash A. Mody 232.62 Mr. Dilip J Kunkolienkar 102.81</p> <p style="text-align: right;">335.43</p>	
<p>vii) Salary (including defined contribution plan)</p> <p>Relative of Key Management Personnel</p> <p>Ms Supriya Mody 36.05</p> <p style="text-align: right;">36.05</p>	



UNICHEM LABORATORIES LIMITED

Notes forming part of standalone financial statements for the half year ended 30th September, 2019

Particulars	Rs in Lakhs	
	YTD Sep'2019	
viii) Dividend Paid		
Key Management Personnel & Relatives		
Dr. Prakash A. Mody		1,296.78
Mrs Anita Mody		52.94
Ms Supriya Mody		38.00
Ms. Suparna Mody		38.00
Mr. Dilip J. Kunkolienkar		3.02
		1,428.74
Independent Directors		
Mr. Anand Y. Mahajan		0.60
Mr. Prafull Anubhai		0.03
Mr. Prafull D Sheth		0.30
		0.93
ix) Expenses Re-imburement (Establishment and administrative expenses)		
Subsidiaries		
Unichem SA Pty. LTD.		6.22
Unichem Pharmaceuticals (USA) Inc.		48.55
		54.77
x) Siting Fees		
Independent Directors		
Dr. (Mrs.) B. Kinnera Murthy		6.50
Mr. Anand Y. Mahajan		4.00
Mr. Prafull Anubhai		7.50
Mr. Prafull D Sheth		6.00
		24.00
xi) Corporate Social Responsibility		
Enterprise under significant influence of Key Management Personnel		
Adiwasi Unnati Mandal		15.00
		15.00



UNICHEM LABORATORIES LIMITED

Notes forming part of standalone financial statements for the half year ended 30th September, 2019

c) Disclosure of related party balances :

Particulars	Rs in Lakhs	
	YTD Sep'2019	
i) Trade Receivables		
Subsidiaries		
Niche Generics Limited.		2,152.17
Unichem SA Pty. LTD.		347.20
Unichem Farmaceutica Do Brasil Ltda		1,787.28
Unichem Pharmaceuticals (USA) Inc.		20,627.95
Unichem Laboratories Ltd (Ireland)		381.27
		25,295.87
ii) Trade Payables		
Subsidiaries		
Niche Generics Limited.		2.08
Unichem SA Pty. LTD.		2.62
Unichem Farmaceutica Do Brasil Ltda		10.62
Unichem Pharmaceuticals (USA) Inc.		25.73
		41.05
iii) Investments in subsidiaries		
In equity shares		
Niche Generics Limited.		5,856.76
Unichem SA Pty. LTD.		12.14
Unichem Farmaceutica Do Brasil Ltda *		7,086.72
Unichem Pharmaceuticals (USA) Inc.		3,368.09
Unichem Laboratories Ltd (Ireland)		1,269.45
Unichem (China) Pty Ltd		143.73
* fully provided as impairment in value of investment		
		17,736.88
In preference shares		
Niche Generics Limited.		1,164.79
		1,164.79
iv) Guarantees given		
to Banks on behalf of Subsidiary Company		
Unichem Laboratories Ltd (Ireland)		710.96
		710.96
corporate guarantee given on behalf of Subsidiary Company		
Niche Generics Limited.		2,331.00
		2,331.00
v) Deposits paid		
Relative of Key Management Personnel		
Mrs Anita Mody		45.90
Enterprise under significant influence of Key Management Personnel		
Uni - Distributors Pvt. Ltd.		5.00
Uni Trust		2.25
		53.16

d) Contribution to post employment benefit plan :

Particulars	Rs in Lakhs	
	YTD Sep'2019	
Post-employment benefit plans		
Unichem Laboratories Ltd- Employees Superannuation Fund		42.36



UNICHEM LABORATORIES LIMITED

Notes forming part of standalone financial statements for the half year ended 30th September, 2019

- e) Following are Key management Personnel (not covered above) in accordance with provisions of Companies Act, 2013. Details of transactions and balances are below :

Particulars	Rs in Lakhs	
	YTD Sep'2019	
i) Salary (including defined contribution plan)		
Key Management Personnel		
Mrs. Neema Thakore		30.86
Mr. Sandip Ghume		21.14
Mr. Pradeep Bhandari		12.17
ii) Share based payments (ESOP)		
Key Management Personnel		
Mr. Dilip J. Kunkolienkar		33.59

1 Number of option pending to be exercised by Mr. Dilip Kunkolienkar as on 30th September, 2019 are 246,176

2 Key Managerial Personnel and their Relatives who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits' in the financial statements. As these employee benefits are lump sum amounts provided on the basis of actuarial valuation, the same is not included above. Further, it also does not include actual payments of gratuity and leave encashment. Also, re-imbursment of expenses to KMP and their relatives are not included above.

3 Related party contracts / arrangements have been entered in ordinary course of business and are approved by the board of directors/ shareholders as applicable.

- f) In view of the Management , equity investment in Synchron Research Services Pvt Ltd will not result the investee company becoming a related party since there is no control / influence over operations :

The summary of transactions with Synchron Research Services Pvt. Ltd are as follows:

Particulars	Rs in Lakhs	
	YTD Sep'2019	
Rent Income (net of indirect tax)		21.96
Deposit received		7.50

